Regulated markets hold key for Alembic as it eyes its first ANDA approval
This article was originally published in Scrip
The Indian company, Alembic, expects its own active pharmaceutical ingredient (API) and ANDA projects in regulated markets to drive future growth. The company, which expects to receive its first ANDA approval in the US within the next quarter or so, has already firmed up distribution alliances in the US and Europe as some of its projects bear fruit there.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.